Effect of continuous positive airway pressure combined to nebulization on lung deposition measured by urinary excretion of amikacin  by Reychler, Gregory et al.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 2051–20550954-6111/$ - see fro
doi:10.1016/j.rmed.
Corresponding au
Louvain, Avenue Hip
E-mail addresses
(J. Roeseler), Thys@Effect of continuous positive airway pressure
combined to nebulization on lung deposition
measured by urinary excretion of amikacin
Gregory Reychlera,b,, Teresinha Lealc, Jean Roeselera,d, Fre´de´ric Thysd,
Nicolas Delvaud, Giuseppe LiistroeaDepartment of Physical Medicine and Rehabilitation, Cliniques Universitaires Saint-Luc, Universite´ Catholique de Louvain,
Avenue Hippocrate 10, 1200 Brussels, Belgium
bDepartment of Pediatry, Cliniques Universitaires Saint-Luc, Universite´ Catholique de Louvain, Avenue Hippocrate 10,
1200 Brussels, Belgium
cDepartment of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Universite´ Catholique de Louvain,
Avenue Hippocrate 10, 1200 Brussels, Belgium
dDepartment of Emergency and Intensive Care, Cliniques Universitaires Saint-Luc, Universite´ Catholique de Louvain,
Avenue Hippocrate 10, 1200 Brussels, Belgium
ePneumology Unit, Cliniques Universitaires Saint-Luc, Universite´ Catholique de Louvain, Avenue Hippocrate 10,
1200 Brussels, Belgium
Received 16 December 2006; accepted 3 June 2007
Available online 12 July 2007KEYWORDS
Nebulizer;
Lung deposition;
Continuous positive
airway pressure;
Urinary monitoringnt matter & 2007
2007.06.003
thor. Department
pocrate 10, 1200
: Gregory.reychler
rean.ucl.ac.be (F.Summary
Continuous positive airway pressure (CPAP) is frequently used in patients attending
emergency units. Its combination with nebulization is sometimes necessary in those
patients presenting with a CPAP dependency.
Study objective: To compare lung deposition of amikacin delivered by a classical jet
nebulizer (SideStream; Medic-Aid; West Sussex, UK) used alone (SST) or coupled to a CPAP
device (Boussignac; Vygon; Belgium).
Method: Amikacin (1 g) was nebulized with both devices in six healthy subjects during
5min on spontaneous breathing. A 1-week wash-out period between each nebulization was
applied. Lung deposition was indirectly assessed by urinary monitoring of excreted amount
of amikacin.
Results: Total daily amount of amikacin excreted in the urine was significantly lower with
CPAP than with SST (1.97% initial dose versus 4.88% initial dose, po0.001) with a
corresponding mean ratio CPAP/SST of 0.41. The residual amount of amikacin in theElsevier Ltd. All rights reserved.
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G. Reychler et al.2052nebulizer was higher with CPAP than with SST (607mg versus 541mg) but the difference
was not significant (p ¼ 0.35).
Conclusion: These data suggest that the amount of amikacin delivered to healthy lungs is
2.5-fold lower with CPAP than with SST for the same nebulization time and that the
nebulization time when using CPAP should be increased to reach the same amount of drug
delivered with a classical jet nebulizer.
& 2007 Elsevier Ltd. All rights reserved.Introduction
The Boussignac valve delivery device was described in 1989.
The device easily allows applying, at a low cost, continuous
positive pressure that contributes to decrease the inspira-
tory work of breathing and to improve gas exchange. Its
lightweight and small size may represent major advantages
facilitating transport and mobilization of the apparatus that
could be of particular interest for emergency units.
Nebulization is a frequently used method for drug delivery
to the lungs of patients attending emergency units. A major
aim is to administer drugs into the lungs as quick as possible
and with lower systemic absorption than that obtained by
other routes of administration. The amount of drug
delivered to the lungs is essential to the clinical response.
Various modalities of administration and devices have been
developed and recent evidence-based guidelines assert
nebulizers, pressurized metered-dose inhalers or powder
inhalers can be equally efficient for delivering bronchodila-
tors.1 Clinical setting must be taken into account in the
choice of the device. In emergency units, nebulizers are
often preferred to other inhaled modalities due to non-
cooperation of patients. Respiratory distress and elder or
pediatric patients account for poor cooperation.
In several clinical situations, the clinician may prefer to
use continuous positive airway pressure (CPAP) simulta-
neously with nebulization but consequences of this associa-
tion on lung deposition of nebulized drugs remain unclear.
This study aimed at evaluating in a clinical setup the effects
of the adjunction of a Boussignac valve positive airway
pressure delivery to a nebulizer on the lung deposition of
drug. Comparison was performed by sampling the daily
urinary excretion of a single dose of nebulized amikacin
which presents minimal oral absorption,2 negligible hepatic
metabolization3 and short half-life. This procedure allows
non-invasive estimation of the mass of drug deposited into
the lungs and quantification of lung deposition because
aminoglycosides are not absorbed from the digestive
tract.4–6Figure 1 Illustration of the experimental combination of
Boussignac valve with the nebulizer.Material and methods
Subjects
After study approval by our Institutional medical Ethics
Committee, six non-smoker healthy male volunteers (mean
age ¼ 27.372.2) were recruited. Each volunteer performed
a spirometry according to the ATS/ERS guidelines7 and
results were expressed in percentage of predicted value.8The subjects did not receive any antibiotic or aerosolized
drug during the month preceding the experiments. All
declared to be free from allergy to aminoglycosides.
Nebulization
A well-known and validated jet nebulizer (Sidestreams;
Medic-Aid; West Sussex, UK) (SST) was chosen as the
reference nebulizer. It is driven by air supply and a flow of
10 Lm1 according to manufacturers’ recommendations.
In the Boussignac valve (CPAP Boussignac, Vygon, Belgi-
que) (CPAP), the positive pressure is induced by injection of
a gas under high flow through small deflected side channels.
Gas propagation produces a hyperpressure creating a
positive pressure to the patient side of the Boussignac valve
and a depression to the other side (Fig. 1). CPAP was
combined to the expiratory gate of Sidestream. Driving
airflow of the valve was adapted according to pressure
monitoring to obtain 6 cm H2O of positive airway pressure.
Nebulized drug solution
Amikacin sulfate (Bristol-Myers Squibb, Belgium) was dis-
solved in 4mL 0.9% NaCl solution to a concentration of
250mgmL1. The solution was nebulized during 5min with
each device. This duration was chosen following preliminary
testing where sputtering point was considered as end-point
of nebulization with Sidestream. Fill volume was less than
maximal fill volume recommended (6mL).
Protocol
Nebulizations were performed randomly with the SST
alone or with the SST connected to the Boussignac valve.
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Table 1 Comparison of respiratory data obtained
during nebulization with the continuous positive airway
pressure (CPAP) device and the reference apparatus (SST)
in six healthy subjects.
CPAP SST
Vt (L) 1.0670.4 0.7670.1
RF (min1) 9.172.6* 13.771.5
VE (Lmin1) 9.071.9 10.370.8
I:E 0.5170.05* 0.8870.07
Results are expressed as mean7SD. Vt, tidal volume; RF,
respiratory frequency; VE, minute ventilation. *po0.001.
Effect of CPAP on nebulization 2053They were realized at the same time of the day, in the same
room and at ambient temperature (mean ¼ 23.2 1C70.8)
during spontaneous continuous breathing. A wash out period
of 1 week between both inhalations was respected for each
subject. This period allows eliminating all residual drug due
to its short half-life. Just before the experiments, the
urinary bladder of the subjects was emptied. Then during
the 24 h following the nebulization, urine samples were
collected at each spontaneous micturition. Their volume
was precisely measured and the exact timing of the
micturition was recorded.
Samples were assayed for amikacin by fluorescence
polarization immuno-assay (FPIA) (TDx, Abbott Labora-
tories, Diagnostic Division, IL, USA).
Each subject inhaled the same solution with both devices
in the same conditions. During the nebulization, the
subjects were comfortably seated and breathed sponta-
neously through mouthpiece wearing a nose clip.
Measurements
During the nebulization, respiratory parameters such as
tidal volume (Vt; L), respiratory frequency (RF; min1) and
minute ventilation (VE; Lmin1) were monitored by induc-
tance plethysmography (Respitraces, Ambulatory Monitor-
ing Inc., Ardsley, NY, USA) after calibration with a
spirometer.
An aliquot of 100 mL of initial and final solutions was
sampled by pipetting in order to measure the amikacin
concentration in the collector of the nebulizer. Residual
volume was measured by pipetting after a 5min rest period.
Residual amount of drug was calculated by multiplying
residual volume and final concentration.
Total daily amount of amikacin excreted in the urine (Cu
max) was calculated by the sum of cumulative amikacin
amount measured at each micturition (Cu). The ratio
between Cu max obtained after nebulization combined with
positive airway pressure and Cu max obtained after
nebulization alone allowed evaluating the efficiency of the
nebulization while combined to a Boussignac valve. The
constant of elimination (Ke) was calculated from the fitted
curve of the cumulated amount of amikacin excreted in the
urine plotted versus the time.
The equation is
Cu ¼ Cu maxð1 eKetÞ.
Statistical methods
Results are expressed as mean7SD. Statistical tests were
performed using SPSS 11.5 (Business unit of SAS, Cary,
NC27513).
Residual amount was compared using an unpaired
Student’s t-test. Student’s paired t-test was used for
comparisons of pharmacokinetic parameters between the
modalities.
Results
Mean anthropometric parameters of the six subjects were as
follows: height ¼ 17973 cm and weight ¼ 7774 kg. They allpresented a normal lung function (FVC ¼ 97.873.4% pred.
and FEV1 ¼ 93.672.6% pred.).
The respiratory parameters are summarized in Table 1.
Respiratory frequency was significantly lower when compar-
ing CPAP with SST. No significant difference was found when
comparing tidal volume and minute ventilation obtained
with both devices.
Residual amount of amikacin (in the collector) was a
slightly higher with CPAP than with SST (607 versus 541mg)
but the difference was not significant (p ¼ 0.35).
Total daily amount of amikacin excreted in the urine was
significantly lower with CPAP when comparing with SST
(21.0772.95 versus 52.1174.18mg) (po0.001). Proportion
of the daily excreted amount and the initial dose of
amikacin was, respectively, 4.9% and 1.9% for SST and CPAP
(po0.001). The mean ratio Cu max (CPAP)/Cu max (SST)
was 0.4170.05. The mean number of micturition was,
respectively, 5.871.2 and 5.871.7 for CPAP and SST. The
mean volume of urine was, respectively, 2.1 L70.6 and
2.2 L70.7 for CPAP and SST. Comparable values (0.171
versus 0.143, p ¼ 0.27) were obtained for the elimination
constant of the drug following nebulization with both
devices.
Lung function, anthropometric parameters, and respira-
tory parameters were not correlated with Cu max.Discussion
We here highlight that a lower dose of amikacin was
delivered to healthy lungs with the combination of a
Boussignac valve (CPAP) with a nebulizer (SST) than with
the nebulizer (SST) alone.
Some of the methodological aspects of the study,
compared to presently available published data should be
addressed. According to a well-known feature,9 we found
that a small fraction corresponding to 4.9% of initial dose
was excreted in the urine when using the SST device.
CPAP produces a decrease of respiratory frequency10 and
an increase of functional residual capacity. That should be
beneficial to lung deposition.11 Although we observed this
decrease of respiratory frequency with CPAP, lung deposition
was lower in this configuration. We can note that, excepted
for I:E ratio, all respiratory parameters presented a higher
coefficient of variation during CPAP than during nebulization
alone. No correlation was found between pattern of
breathing and lung deposition.
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G. Reychler et al.2054While the total daily urinary amount of aminoglycoside
excreted was significantly lower with CPAP, constant of
elimination that informs on the depth of the penetration of
a nebulized drug into the lungs12 was not different. Similar
kinetics suggests an identical localization of deposition
without other precision on this localization. Then the
difference in the urinary excretion should be due to
different aerosol efficacy or intersubject variability. As the
nebulizations were performed in paired conditions, the
influence of anatomical and mechanical intersubject varia-
bility was eliminated as confounding factors.
In agreement with previous data,13 the concentration of
the drug in the residual solution was increased at the end of
nebulizations with both devices. Although not significant,
higher amount of amikacin at the end of nebulizations with
CPAP can be explained by a higher evaporation of the
solvent due to flow induced into the collector.
Difference of lung dose without difference of residual
amount could be explained by two elements. Due to lower
I:E ratio during nebulization with CPAP, losses were probably
higher during expiratory phase even though absence of filter
on expiratory way do not allow to confirm this hypothesis.
Indeed, Parkes had observed a decreased inhaled dose when
a CPAP was combined with a nebulization.14 Moreover,
additional flow produced by CPAP could increase impaction
in mouth and then contribute to lower lung dose.
Moreover combining other modalities of positive airway
pressure (BiPAP, IPV, IPPB) and nebulization have been
studied with similar results.15–19
Healthy subjects were enrolled to limit the effect of
underlying lung diseases which can modify lung deposition,
pattern of breathing9,20 and alveolocapillary permeability.21
Variability in urinary excretion of nebulized aminoglycosides
and in rate of absorption have been previously reported in
cystic fibrosis patients.4,22 All these elements justify the
choice of healthy subjects to evaluate in a first time the
effect of CPAP on lung deposition. Unfortunately, these
limitations preclude extrapolating our data to patients with
respiratory disease.
Although a relatively small number of subjects have been
investigated, the group was homogeneous in terms of lung
function and a lower lung deposition has been measured
with the combination of the Boussignac valve to a nebulizer
in all individuals.
FPIA was used as method for sampling. This method offers
a good reproducibility with coefficients of variation lower
than 4% and is correlated with well-established enzyme
multiplied immunoassay technique (EMIT) and radioimmu-
noassay (RIA) methods.23
Limitations of this study are the lack of information
provided by pharmacokinetic approach on the site of
deposition, on the effect of over-distension of the lung
due to CPAP, and on the potential benefit for patients
needing CPAP simultaneously to nebulization. Complemen-
tary studies with radiolabeled drugs would clarify the effect
of aeration due to CPAP on lung deposition.
In conclusion, this study confirms the predictions of in
vitro results. The amount of amikacin delivered to the lung
of young healthy adult subjects was 2.5-fold lower with
CPAP than with SST for a fixed nebulization time which is less
favorable to the therapeutic efficacy of nebulization,
certainly in the emergency unit. Nebulization time whenusing CPAP should be increased to reach the same amount of
drug delivered with a classical jet nebulizer.
Due to these negative results obtained on healthy
subject, it could be interesting to measure effect of the
combination CPAP-nebulization on lung administration of a
drug and its clinical efficacy in patients requiring this
treatment. Although clinical efficacy of CPAP seems un-
affected by combination with a nebulizer, more data are
needed to allow the use of this combination in routine with
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